Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
RVMD
#514
Revolution Medicines, Inc. Common Stock
102.020
0
+0.79%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
+0.79%
Monatliche Änderung
+3.01%
6 month change
+84.15%
Jahresänderung
+84.15%
Vorheriger Schlusskurs
101.220
0
Open
102.020
0
Bid
Ask
Low
102.020
0
High
102.020
0
Volumen
349
Märkte
Aktien
Gesundheitswesen
RVMD
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
168.22 M
185.91 M
186.27 M
186.93 M
193.32 M
198.17 M
—
Valuation ratios
Enterprise value
7.43 B
7.59 B
6.25 B
6.47 B
8.81 B
15.4 B
36.94 B
Price to earnings ratio
-12.32
-12.22
-8.82
-8.14
-8.98
-13.39
-39.32
Price to sales ratio
6 915.56
—
5 246.72
3 688.56
3 511.79
—
—
Price to cash flow ratio
12.6
13.16
10.35
9.64
11.31
16.87
48.17
Price to book ratio
0.99
3.24
0.81
0.84
1.09
9.28
12.02
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
-0.09
-0.08
-0.09
-0.1
-0.14
-0.15
-0.48
Return on equity %
-0.1
-0.09
-0.1
-0.13
-0.19
-0.22
-0.65
Return on invested capital %
-286.23
-309.69
—
—
—
96.88
—
Gross margin %
—
—
100
100
100
100
400
Operating margin %
—
—
-18.99 K
-43.4 K
-50.12 K
-43.31 K
-155.81 K
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
—
—
-16.83 K
-40.62 K
-48.52 K
-43.7 K
-149.67 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
14.24
14.2
13.46
11.79
8.05
7.14
40.45
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0
0
0
0
0
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.78
-0.82
-1.03
-1.18
-1.1
-1.44
-4.75
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
9.29
13.65
11.18
11.33
10.21
10.65
43.37
Net current asset value per share
9.46
13.88
11.35
11.54
10.45
10.91
44.25
Tangible book value per share
8.96
13.08
10.67
9.52
8.07
8.21
36.46
Working capital per share
8.8
12.9
10.5
10.56
9.15
9.39
39.6
Book value per share
9.39
13.5
11.05
9.89
8.44
8.58
37.96
Nachrichten
UBS startet Coverage für Revolution Medicines mit Kaufempfehlung – Hohes Potenzial bei RAS-Inhibitor
UBS assumes coverage on Revolution stock with buy rating on RAS inhibitor potential
RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View
Piper Sandler hebt Kursziel für Revolution Medicines deutlich an – Vertrauen in Wirkstoff wächst/n
Piper Sandler raises Revolution stock price target on drug confidence
Needham lowers Revolution stock price target to $145 on higher costs
Wells Fargo hebt Kursziel für Revolution Medicines nach Studienfortschritten an
Wells Fargo raises Revolution stock price target on trial progress
Revolution Medicines, Inc. (RVMD) Q4 2025 Earnings Call Transcript
Revolution Medicines: Hohe Investitionen und steigender Verlust im 4. Quartal 2025
Revolution Medicines in spotlight as earnings loom after M&A chatter
BB Biotech mit 660 % Gewinnplus in 2025 – Ausblick für 2026 jedoch verhalten